ClinicalTrials.gg
Status unknownNCT05498740UltraFuture IUpdated Aug 12, 2022

Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia

An interventional study of Drug eluting Balloon in Peripheral Arterial Disease (PAD), sponsored by Zhejiang Zylox Medical Device Co., Ltd.. Status unknown at 24 sites in China. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-12.

Sponsored by Zhejiang Zylox Medical Device Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.

Planned enrollment
19th of 53
200 · median 167
Started
2022
with 7 others
No phase
34 of 80
13 open now
Registered
45th of 80
by date
Lead sponsor
6 of 80
Zhejiang Zylox Medical Device Co., Ltd.

Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 19th largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2022, is one of 34 with no phase, and was the 45th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Peripheral Arterial Disease with a site in China, or all of them as a file.
02

Study summary

The objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the Drug-coated Balloon catheters in the treatment of the Superficial Femoral Artery (SFA) and Popliteal Arteries (PA).

03

Conditions studied

  • Peripheral Arterial Disease (PAD)
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old and ≤85 years old
  2. Rutherford clinical category classification:2-5
  3. Significant stenosis (≥50%) or occlusions of lesion(s) located in the superficial femoral artery an /or the popliteal artery
  4. At least one patent native outflow artery to the ankle free from significant lesion as confirmed by angiography
  5. Subject has provided written prior to participation , understands the purpose of this trail and agrees to comply with all protocol-specified examinations and follow-up appointments.

Exclusion criteria

Exclusion Criteria:

  1. Aneurysms near target lesions or popliteal aneurysms.
  2. The guide wire cannot pass smoothly through the target lesion.
  3. Known allergy to contrast agents, heparin or paclitaxel.
  4. Patient already enrolled in other (interventional) studies that would interfere with study endpoints or may enroll in other studies after enrollment in this clinical trial.
  5. Pregnancy or female patient with child bearing potential not taking adequate or currently lactating.
  6. Other comorbidities, which in the opinion of the investigator limit longevity or likelihood of compliance with protocol follow up.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    drug eluting balloon catheter

    use drug eluting balloon catheter to treat the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery

    Device: Drug eluting Balloon

Interventions

  • DeviceDrug eluting Balloon

    Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.

06

What researchers measure

Primary outcomes

  1. rate of device success

    Time frame: intraoperative

  2. rate of procedural success

    Time frame: intraoperative

  3. rate of technical success

    Time frame: intraoperative

  4. rate of primary patency of target lesion

    Time frame: 12 months

  5. rate of primary patency of target lesion

    Time frame: 24 months

  6. rate of Clinically-driven TLR

    Time frame: 12 months

  7. rate of Clinically-driven TLR

    Time frame: 24 months

  8. rate of TLR

    Time frame: 1 month

  9. rate of TLR

    Time frame: 12 months

  10. rate of TLR

    Time frame: 24 months

  11. rate of Clinically-driven TVR

    Time frame: 12 months

  12. rate of Clinically-driven TVR

    Time frame: 24 months

  13. rate of TVR

    Time frame: 1 month

  14. rate of TVR

    Time frame: 12 months

  15. rate of TVR

    Time frame: 24 months

  16. change in Rutherford clinical category (target limb)

    Time frame: 12 months

  17. change in Rutherford clinical category (target limb)

    Time frame: 24 months

  18. change in ankle brachial index(ABI)

    Time frame: 12 months

  19. change in ankle brachial index(ABI)

    Time frame: 24 months

  20. rate of SAE

    Time frame: 12 months

  21. rate of SAE

    Time frame: 24 months

  22. rate of All-cause mortality

    Time frame: 1 month

  23. rate of All-cause mortality

    Time frame: 12 months

  24. rate of All-cause mortality

    Time frame: 24 months

  25. rate of Major amputation

    Time frame: 1 month

  26. rate of Major amputation

    Time frame: 12 months

  27. rate of Major amputation

    Time frame: 24 months

  28. rate of target lesion thrombosis

    Time frame: 12 months

  29. rate of target lesion thrombosis

    Time frame: 24 months

  30. Rate of adverse events

    Time frame: intraoperative

  31. Rate of adverse events

    Time frame: 1 month

  32. Rate of adverse events

    Time frame: 12 months

  33. Rate of adverse events

    Time frame: 24 months

07

Study locations

24 of 24 sites recruiting
  • Xuanwu hospital
    Beijing, China
    Recruiting
    • Yongquan Gu · Contact
  • Affiliated Hospital of Chengde Medical College
    Chengde, China
    Recruiting
    • Hong Zhang · Contact
  • The Third People's Hospital of Chengdu
    Chengdu, China
    Recruiting
    • Chi Cui · Contact
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, China
    Recruiting
    • Ming Qi · Contact
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, China
    Recruiting
    • Lei Song · Contact
  • Guangzhou Huaqiao hospital
    Guangzhou, China
    Recruiting
    • Yan Zhang · Contact
  • Hospital of Traditional Chinese Medicine affiliated to Guangzhou Medical University
    Guangzhou, China
    Recruiting
    • Meng Du · Contact
  • The Third Affiliated Hospital of Guangzhou Medical University
    Guangzhou, China
    Recruiting
    • Chenyu Yang · Contact
  • The First Affiliated Hospital of Harbin Medical University
    Ha'erbin, China
    Recruiting
    • Bing Liu · Contact
  • Hangzhou First People's Hospital
    Hangzhou, China
    Recruiting
    • Xin Fang · Contact
  • First Hospital of Lanzhou University
    Lanzhou, China
    Recruiting
    • Xiaojun Shu · Contact
  • Ningbo huamei hospital
    Ningbo, China
    Recruiting
    • Dehai Lang · Contact
  • Qingdao Municipal Hospital
    Qingdao, China
    Recruiting
    • Dalin Li · Contact
  • Ruian People's Hospital
    Rui'an, China
    Recruiting
    • Changsheng Shi · Contact
  • Shanghai Ninth People'S Hospital
    Shanghai, China
    Recruiting
    • Minyi Yin · Contact
  • Zhongshan Hospital
    Shanghai, China
    Recruiting
    • Weiguo Fu · Contact
  • Northern Theatre General Hospital
    Shenyang, China
    Recruiting
    • Hong Jiang · Contact
  • Tianjin Medical University General Hospital
    Tianjin, China
    Recruiting
    • Xiangchen Dai · Contact
  • Tianjin People's Hospital
    Tianjin, China
    Recruiting
    • Li Su · Contact
  • Weifang People's Hospital
    Weifang, China
    Recruiting
    • Jiefeng Zhang · Contact
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, China
    Recruiting
    • Jingyong Huang · Contact
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, China
    Recruiting
    • Xiangtao Zheng · Contact
  • The First Affiliated Hospital of Xi 'an Jiaotong University School of Medicine
    Xi'an, China
    Recruiting
    • Hongyan Tian · Contact
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Xinjiang, China
    Recruiting
    • Sheng Guan · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2022, 7 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 7 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2022
First posted
Aug 12, 2022
StartActual
May 4, 2022
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2024
Last update
Aug 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05498740
Lead sponsor
Zhejiang Zylox Medical Device Co., Ltd.
Responsible party
Sponsor
First posted
Aug 12, 2022
Start date
May 4, 2022
Primary completion
Dec 2022 (estimated)
Completion
Dec 2024 (estimated)
Last update
Aug 12, 2022

Study contacts

Jie Liang
Contact
jie.liang@zyloxmedical.com
13819565660
Weiguo Fu
principal investigator · Shanghai Zhongshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion